Trial · NCT02665260
Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
NCT02665260, Phase 2, Completed, Montefiore Medical Center; results first posted 2017-05-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum. Trials, record NCT02665260. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02665260
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum
- NCT number
- NCT02665260
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 94 participants, actual
- Lead sponsor
- Montefiore Medical Center
- Conditions
- Molluscum Contagiosum
- Interventions
- Cantharidin, Placebo, Gauze occlusion bandage
- First posted
- 2016-01-27
- Last updated
- 2017-05-05
- Results first posted
- 2017-05-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Subjects Who Achieve Complete Clearance at 6 Weeks | 6 weeks | Assess number of subjects who achieve a lesion count of zero at 6 weeks (end of open-label phase) |
| Secondary | Number of Subjects Who Experienced an Adverse Event | 33 weeks | Number of subjects who experienced an adverse event as assessed by patient-reported outcomes questionnaire at each visit |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects Who Achieve Complete Clearance at 6 Weeks | 6 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Experienced an Adverse Event | 33 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Cantharidin With Occlusion | Number of subjects achieving lesion clearance | 10 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Cantharidin Without Occlusion | Number of subjects achieving lesion clearance | 7 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Placebo With Occlusion | Number of subjects achieving lesion clearance | 2 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Placebo Without Occlusion | Number of subjects achieving lesion clearance | 3 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Cantharidin With Occlusion | Number of subjects not achieving lesion clearance | 14 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Cantharidin Without Occlusion | Number of subjects not achieving lesion clearance | 16 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Placebo With Occlusion | Number of subjects not achieving lesion clearance | 23 | Participants | |
| Number of Subjects Who Achieve Complete Clearance at 6 Weeks | Placebo Without Occlusion | Number of subjects not achieving lesion clearance | 19 | Participants | |
| Number of Subjects Who Experienced an Adverse Event | Cantharidin | Number experiencing adverse event | 0 | Participants | |
| Number of Subjects Who Experienced an Adverse Event | Cantharidin With Occlusion | Number experiencing adverse event | 0 | Participants |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cantharidin With Occlusion | 24 | |
| Overall Study | STARTED | Cantharidin Without Occlusion | 23 | |
| Overall Study | STARTED | Placebo With Occlusion | 25 | |
| Overall Study | STARTED | Placebo Without Occlusion | 22 | |
| Overall Study | COMPLETED | Cantharidin With Occlusion | 22 | |
| Overall Study | COMPLETED | Cantharidin Without Occlusion | 22 | |
| Overall Study | COMPLETED | Placebo With Occlusion | 21 | |
| Overall Study | COMPLETED | Placebo Without Occlusion | 21 | |
| Overall Study | NOT COMPLETED | Cantharidin With Occlusion | 2 | |
| Overall Study | NOT COMPLETED | Cantharidin Without Occlusion | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cantharidin | ||
| Total, all-cause mortality | Cantharidin With Occlusion | ||
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Placebo With Occlusion | ||
| Total, other adverse events | Cantharidin | 0 | 23 |
| Total, other adverse events | Cantharidin With Occlusion | 0 | 24 |
| Total, other adverse events | Placebo | 0 | 22 |
| Total, other adverse events | Placebo With Occlusion | 0 | 25 |
| Total, serious adverse events | Cantharidin | 0 | 23 |
| Total, serious adverse events | Cantharidin With Occlusion | 0 | 24 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02665260
GET https://conductscience.org/api/trials/v1/NCT02665260/registered